Despite significant improvement in the managementof chronic hepatitis B virus (HBV) it remains a publichealth problem, affecting more than 350 million peopleworld
Sorafenib is an effective anti-angiogenic treatment forhepatocellular carcinoma (HCC). The assessment oftumor progression in patients treated with sorafenibis cru